Alpine Immune Sciences Announces Pricing of $150 Million Public Offering

Rhea-AI Summary

Alpine Immune Sciences, Inc. (Nasdaq: ALPN) has announced the pricing of its underwritten public offering of 8,800,000 shares of common stock and pre-funded warrants to purchase up to 3,200,000 shares. The public offering price for the common stock is $12.50 per share, while the pre-funded warrants are priced at $12.499 per warrant. The expected gross proceeds from the offering are approximately $150.0 million. The underwriters have an option to purchase up to an additional 1,800,000 shares of common stock.

SEATTLE--(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the pricing of its underwritten public offering of 8,800,000 shares of its common stock and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to 3,200,000 shares of its common stock, pursuant to its existing shelf registration statement. The shares of common stock are being offered at a public offering price of $12.50 per share and the pre-funded warrants are being offered at a price of $12.499 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The gross proceeds to Alpine from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Alpine, are expected to be approximately $150.0 million. In addition, Alpine has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,800,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. All shares of common stock to be sold in the offering are being sold by Alpine. The offering is expected to close on or about November 9, 2023, subject to customary closing conditions.

Morgan Stanley, TD Cowen and Leerink Partners are acting as joint book-running managers for the proposed public offering. RBC Capital Markets is acting as a bookrunner and Oppenheimer & Co. and H.C. Wainwright & Co. are acting as co-lead managers for the proposed public offering.

A shelf registration statement relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on April 28, 2023 and declared effective by the SEC on May 9, 2023. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone: 1-866-718-1649, or by email at prospectus@morganstanley.com; Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, by telephone at (833) 297-2926, or by email at Prospectus_ECM@cowen.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; RBC Capital Markets, by mail at RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281 or by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding the anticipated closing of the public offering. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to, uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, as well as the other risks identified in our filings with the SEC. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231106758126/en/

Media and Investor Relations Contact:

Temre Johnson

Alpine Immune Sciences, Inc.

ir@alpineimmunesciences.com

media@alpineimmunsciences.com

Source: Alpine Immune Sciences, Inc.

FAQ

What is the ticker symbol for Alpine Immune Sciences, Inc.?

The ticker symbol for Alpine Immune Sciences, Inc. is ALPN.

What is Alpine Immune Sciences, Inc. focused on?

Alpine Immune Sciences, Inc. is a clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases.

What is the public offering price for the common stock?

The public offering price for the common stock is $12.50 per share.

What is the price of the pre-funded warrants?

The price of the pre-funded warrants is $12.499 per warrant.

What are the expected gross proceeds from the offering?

The expected gross proceeds from the offering are approximately $150.0 million.

Do the underwriters have an option to purchase additional shares?

Yes, the underwriters have an option to purchase up to an additional 1,800,000 shares of common stock.